Surface Oncology Competitors, Revenue and Alternatives

Claim your profile

Overview

Location:
Boston, MA USA
Total Funding:$143M
Industry:Biotech
Founded:2014
Lead Investor(s):N/A

Industry Ranking

Estimated Revenue & Financials

  • Surface Oncology's estimated annual revenue is currently $59.4M per year.
  • Surface Oncology received $35.0M in venture funding in January 2015.
  • Surface Oncology's estimated revenue per employee is $618,927
  • Surface Oncology's total funding is $143M.

Employee Data

  • Surface Oncology has 96 Employees.
  • Surface Oncology grew their employee count by 26% last year.
  • Surface Oncology currently has 4 job openings.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingPricing
Ultivue
$8.7M56-12%N/AN/A
Ohana Bioscienc...
$8.7M5660%N/AN/A
Compass Therape...
$16.4M10614%N/AN/A
Cell Signaling ...
$89.4M577N/AN/AN/A
Momenta Pharmac...
N/A220N/AN/AN/A
Emulate
$15.3M99-17%N/AN/A
ArQule
N/A94N/AN/AN/A
Hamilton Storag...
$17.2M1119%N/AN/A
Alnylam Pharmac...
$74.9M127731%N/AN/A
Transgenomic
N/A47N/AN/AN/A
Missing a competitor? Contribute!?
Submit

Surface Oncology is a clinical-stage immuno-oncology company focused on using its specialized knowledge of the biological pathways critical to the immunosuppressive tumor microenvironment (TME) for the development of next-generation therapies to help patients suffering with cancer. Recent advances in understanding how the immune system fights cancer has created a first wave of immunotherapies with profound benefits for some patients. These first-generation therapies, or "checkpoint inhibitors", have been groundbreaking, but only a relatively small subset of patients is deriving long-term benefit. We believe that the lack of a broad and sustained clinical response is because these first-generation therapies only target one component of the immunosuppressive TME and a broader, more multi-faceted therapeutic approach is required. Surface is leveraging its deep understanding of TME biology to target factors and cells that suppress patients anti-tumor immune response. Our broad attack on the TME has the potential to convert patients non-responsive cold tumors into immune-active ones. We are committed to developing a pipeline of next-generation immunotherapies that deliver lasting benefits to patients suffering from cancer as quickly as possible. From a discovery perspective, Surface leverages its world-class SAB to identify new targets and takes an aggressive approach towards generating diverse, highly-specific antibodies, which allows our scientists to thoroughly explore the relevant biology. We utilize multiple antibody generation platforms and have established relationships with several best-in-class antibody technology partners. Our antibody discovery approach generates therapeutic-quality antibodies, as well as unique tools to explore the biology of the tumor microenvironment. The company has a strategic collaboration with Novartis and is supported by leading healthcare investors, including Atlas Venture, NEA, F-Prime, Lilly Ventures and Amgen Ventures.

keywords:Biotechnology,Healthcare,Pharmaceuticals

96

Number of Employees

$59.4M

Revenue (est)

4

Current Jobs

26%

Employee Growth %

$143M

Total Funding

N/A

Valuation

N/A

Accelerator

N/A

Type

Executive Contacts

NameTitleEmail
Vito PalombellaChief Scientific Officer
Kerry WhitePrincipal ScientistEmail Available
Shannon Rourke DevensVice President
Abhay PatkiSenior Director, Clinical ScienceEmail Available
Kate SullivanSenior Manager, Qc And StabilityEmail Available
Christina RiordanSenior Director ToxicologyEmail Available
Devan MoodleyPrincipal Scientist
Chris BeansManager, IT OperationsEmail Available
Caroline ArmetResearch Associate/Lab Manager
Nicole Carvalho"i Am Not The Corporate Police...." - Nmc Senior Manager, QaEmail Available

Surface Oncology News

09/07/2019 - Ramy Ibrahim, MD to Join Surface Oncology Board of Directors

CAMBRIDGE, Mass., Sept. 03, 2019 (GLOBE NEWSWIRE) -- Surface Oncology (NASDAQ:SURF), today announced Ramy Ibrahim, M.D., will ...

09/08/2019 - Surface Oncology Inc (NASDAQ:SURF) Short Interest Update

Surface Oncology Inc (NASDAQ:SURF) was the target of a large drop in short interest in the month of July. As of July 31st, there was short ...

09/03/2019 - Surface Oncology to Present at the Baird 2019 Global ...

CAMBRIDGE, Mass., Sept. 03, 2019 (GLOBE NEWSWIRE) -- Surface Oncology (SURF), a clinical-stage immuno-oncology company ...

Surface Oncology Funding

DateAmountRoundLead InvestorsReference
2015-01-09$35.0MAMultipleArticle

Surface Oncology Executive Hires

DateNameTitleReference
2015-05-08Detlev BiniszkiewiczPresident & CEOArticle
2016-01-29Vito J. PalombellaChief Scientific Officer.Article
2016-12-16Robert RossChief Medical OfficerArticle
2017-01-05Daniel LynchExecutive ChairmanArticle
2017-02-08Jeff GoaterChief Business OfficerArticle
2018-02-13Jeff GoaterCEOArticle